Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar ravens9111 (63.28) Submitted: 3/26/2012 5:06:41 PM : Outperform Start Price: $39.42 CELG Score: -4.33

My favorite biotech stock. Although there may be better spec plays out there, CELG is already established with high earnings growth and a compelling valuation. This company has many drugs in the pipeline to continue its growth for the future.

Featured Broker Partners


Advertisement